Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.80 -3.23%
EPS Growth %: -50.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OCCI, IPX, ALZN, More
EPS Growth %: -50.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.27), $0.14 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $33 million versus the consensus estimate of $29.98 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- Moody’s upgrades Cushman & Wakefield rating to Ba3 on debt reduction
- KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
